Late-Breaking Abstracts
Skip to Content


Abstracts submitted during the late-breaking time, January 12 - February 9, 2024, will only be considered if the data analysis were NOT available before the ATC original abstract submission deadline date of December 18, 2023. There are no exceptions.

There will be very limited slots for late-breaking presentations. Please include a brief justification (on the Questionnaire submission page) why this should be considered a "late breaking abstract".

Clinical Trial Abstract Submissions

ATC has incorporated for the second year in a row, a category for Late Breaking Abstracts titled Clinical Trials. This category invites submissions of abstracts describing results of clinical trials in which results become available after the initial abstract deadline and can be presented at the conference.

Important for Late Breaking Clinical Trial Category:
We invite submissions that highlight ongoing trials of importance in transplantation without interim or final results available.

Call for Late-Breaking Abstracts Timeline

The below timeline has been put in place for submission, review, and status notifications.

February 2024

  • February 9, 2024, 11:59 PM PT - Late breaking abstract submission deadline.
  • Original abstract status notifications will be sent.

March 2024

  • Late breaking abstract status notifications will be sent.


General Information

In-Person Participation

This year, ATC will host an In-Person Congress which will take place at the Pennsylvania Convention Center in Philadelphia, PA, USA.

All ATC Speakers and Moderators are expected to travel to Philadelphia, PA to participate in-person.

Target Audience

The American Transplant Congress is designed for physicians, surgeons, scientists, nurses, organ procurement personnel and pharmacists who are interested in the clinical and research aspects of solid organ and tissue transplantation. The meeting will provide the most current information in the field of transplant science.


A variety of formats are planned that will encourage the exchange of new scientific and clinical information and support an interchange of opinions regarding care and management as well as socioeconomic, ethical, and regulatory issues relevant to organ and tissue transplantation.

Abstract submissions will be presented through peer reviewed oral and poster presentations.


The purpose of the meeting is to:

  • Review and evaluate the latest clinical and basic science advances in transplantation science, medicine and surgery;
  • Investigate recent developments in transplant biology, immunology and organ preservation;
  • Examine the broad but critical issues in transplantation, including social and policy issues.

Submitting an abstract to the American Transplant Congress means that it will be peer reviewed and may be accepted for either an oral or a poster presentation. All accepted abstracts will be published in an online supplement to the American Journal of Transplantation (AJT), the joint journal of the American Society of Transplant Surgeons (ASTS) and American Society of Transplantation (AST). You may submit as many abstracts as you wish

Viewing Formats

All accepted abstracts will be accessible in the following formats:

  1. June Online Supplement Issue of the American Journal of Transplantation (AJT).
  2. ATC Mobile Application
  3. ATC Congress Abstract Website
  4. ATC Virtual Platform Abstract Library

Read the ATC abstract Embargo policy below for more information.

Abstract Policies & Guidelines

Previous Presentation of Abstracts

Abstracts will be considered for presentation if they have NOT been previously published as an article at the TIME OF SUBMISSION.

Abstract Preparation

Abstracts must conform exactly to the instructions provided for electronic submission (by the American Transplant Congress). Click here for the full instruction document. This document will also be available in the ATC Program User Portal.

Abstracts must be submitted in English and all presentations will be in English. The abstract character limit is 2,750 characters. The character count includes: Abstract Title, Abstract Structure, Authors/Institutions, Table (320 characters), and Figures (320 characters) and does NOT include spaces.


Abstracts accepted for oral or poster presentation will be published online in a supplement to the American Journal of Transplantation, the joint journal of the American Society of Transplant Surgeons and the American Society of Transplantation. Abstracts not accepted for presentation will not be published. Abstracts and program will also be posted prior to the meeting on the American Transplant Congress website. Please check this for official publication date.

Informed Consent

Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966:14:103) and must meet all of the requirements governing informed consent of the country in which the study was performed. Any transplant procedures performed must meet with the prevailing ethical standards.

Use of Animals

All studies involving the use of animals must conform to the 1991 revision of "Guiding Principles in the Care and Use of Animals" (American Physiological Association).

Employees of Commercial Interests

ATC recognizes that employees of commercial interests are often involved in research and discovery and encourages these employees to submit abstracts to facilitate the flow of new information. In order to be compliant with the various continuing medical education regulatory bodies, abstracts submitted by employees of commercial interests should not include patient care recommendations. They should focus on the biology, physiology or physics and include content about the discovery process. Abstracts should avoid discussion of products, treatment or diagnostics.

Co-Author Approval

Ensure that all co-authors approve of the abstract submission, publication, and potential presentation.

Abstract Review

Abstracts will be blinded for peer review. Authors should be cautious in using institutional references in the body of the abstract. Do not put author names and/or affiliations in the body. Abstracts which include reference to authors or institutions will not be reviewed.

Changes to Abstract

You are able to edit your abstract until the submission deadline, February 9, 2024. After the submission deadline, no changes are allowed. Any corrections, withdrawals and/or changes will not be accepted after this date. Please note: the submission fee is final and non-refundable regardless of abstract edits or withdrawal.

Abstract Receipt Confirmation

You will receive an email confirmation within two business days of submitting your abstract.

If you submit on the deadline date and do not receive confirmation within two business days, please contact CTI Meeting Technology Technical Support at: or 1.217.398.1792.

Author Disclosure

The submitting author is required to submit their disclosure.

Abstract Clinical Content Validation

All the recommendations involving clinical medicine in a activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in this activity in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Abstract content should not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of CME, or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients. Abstracts containing advocacy of unscientific modalities of diagnosis or therapy will not be considered.

ATC Abstract Embargo Policy

In compliance with the Securities and Exchange Commission's Regulation FD (Fair Disclosure), the accepted abstracts are made available to the public on the ATC website in advance of the meeting. Thus, the first release of the abstracts is a public release on May 1, 2024. Coverage of additional research being presented at the annual meeting is under embargo until the date of presentation.

Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract. However, the ATC continues to require that information that goes beyond that contained within the abstract, e.g., discussion of the abstract done as part of a scientific presentation, is to be embargoed until the start of the scientific sessions. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate.

Journalists failing to abide by the embargo may have their press credentials revoked.


Payment will be displayed as 'CTI' on credit card statements.

Abstract Submission Fee

Submission Fees

A submission fee of $25 for ASTS and/or AST members (first OR last author) or $50 for non-members is required to submit each abstract.

For late breaking abstracts, a submission fee of $50 for ASTS and/or AST members (first OR last author) or $100 for non-members is required to submit each abstract.

  • In order to receive the ASTS/AST abstract submission member fee, you must log in to the ATC Program User Portal with the email associated with the first or last authors membership account.
  • Once you have logged in you will have the option to change the presenting author.
  • Please note the presenting author will be listed as the primary author and will receive all abstract communications.


An abstract submission is not complete until full payment has been submitted online through the ATC Program User Portal. Payment will be displayed as 'CTI' on credit card statements.

View the 2023 Abstracts in the American Journal of Transplantation

Access Journal